Pharmacokinetic Studies of Factor VIII in Chinese Boys with Severe Hemophilia A: A Single-Center Study

被引:9
|
作者
Chen ZhenPing [1 ]
Li PeiJing [1 ]
Li Gang [1 ]
Tang Ling [1 ]
Zhen YingZi [1 ]
Wu XinYi [1 ]
Cheng XiaoLing [1 ]
Hung Luke Koon [2 ]
Blanchette Victor S [3 ]
Poon ManChiu [4 ]
Ding QiuLan [5 ]
Wu RunHui
机构
[1] Hematology Oncology Center, Beijing Children’s Hospital, Capital Medical University, Beijing Key Laboratory of Pediatric Hematology Oncology, National Key Discipline of Pediatrics, Ministry of Education, Beijing 100045, China
[2] Department of Medicine, Pediatrics and Oncology, and Southern Alberta Rare Blood and Bleeding Disorders Comprehensive Care Program, University of Calgary, Foothills Hospital and Calgary Health Region, Calgary, Alberta, T2N2T9, Canada
[3] Department of Pediatrics and Laboratory Medicine, and Hemophilia Clinic, Children’s Hospital of Eastern Ontario and University of Ottawa, Ottawa, Ontario, K1H 8L1, Canada
[4] Department of Laboratory Medicine, Ruijin Hospital, Shanghai Jiaotong University School of Medicine, Shanghai 200025, China
[5] Department of Pediatrics and Child Health Evaluative Sciences, Division of Hematology/Oncology, Research Institute, Hospital for Sick Children, University of Toronto, Toronto, Ontario, M5G 1X8, Canada
关键词
Boys; Factor VIII; Hemophilia A; Pharmacokinetics;
D O I
暂无
中图分类号
R554.1 [];
学科分类号
摘要
Background: Although much attention has been paid to the pharmacokinetics (PKs) of different factor VIII (FVIII) concentrates in persons with hemophilia A (HA), limited information is available in young boys with severe HA. In this study, we aimed to assess the PK parameters of FVIII products in boys with severe HA in China.Methods: A total of 36 boys (plasma-derived [pd]-FVIII,n = 15; recombinant [r] FVIII,n = 21) were enrolled between January 2015 and May 2016 in Beijing Children’s Hospital. PK characteristics of FVIII products were studied according to a reduced 4-sampling time point design (1 h, 9 h, 24 h, and 48 h postinfusion).Results: The mean FVIII half-life (t1/2) was 10.99 ± 3 .45 h (range 5.52- 20.02 h), the meanin vivo recovery (IVR) was 2.01 ± 0.42 IU/dl per IU/kg (range 1.24–3.02 IU/dl per IU/kg) and mean clearance (CL) of FVIII is 4.34 ± 1.58 ml·kg?1·h?1 (range 2.29–7.90 ml·kg?1·h?1). We also analyzed the influence of several parameters that potentially modulate FVIII PK. The age was closely associated with FVIII half-life (R2 = 0.32,P< 0.01). The t1/2 of FVIII increased by 0.59 h per year. Besides age, von Willebrand factor antigen (VWF:Ag) also was associated with FVIII half-life (R2 = 0.52,P< 0.01). Patients with blood Group O had a shorter FVIII half-life than patients with non-O blood group (9.40 ± 0.68 h vs. 12.3 ± 0.79 h,t = 2.70,P= 0.01). The FVIII IVR correlated with age (R2 = 0.21,P< 0.01) and VWF:Ag level (R2 = 0.28,P< 0.01). CL rates were faster in young patients and in those with low-VWF:Ag levels. CL rates of FVIII are higher in blood Group O versus non-blood Group O persons (5.02 ± 0.38 vs. 4.00 ± 0.32 ml·kg?1·h?1,t= 2.53,P= 0.02).Conclusions: Chinese boys with severe HA have similar PK values to other ethnic groups and large differences in FVIII PK between individual patients. Age, blood group, and VWF:Ag levels are important determining factors for FVIII CL.
引用
收藏
页码:1780 / 1785
页数:6
相关论文
共 50 条
  • [1] Pharmacokinetic Studies of Factor VIII in Chinese Boys with Severe Hemophilia A: A Single-Center Study
    Chen, Zhen-Ping
    Li, Pei-Jing
    Li, Gang
    Tang, Ling
    Zhen, Ying-Zi
    Wu, Xin-Yi
    Cheng, Xiao-Ling
    Luke, Koon Hung
    Blanchette, Victor S.
    Poon, Man-Chiu
    Ding, Qiu-Lan
    Wu, Run-Hui
    CHINESE MEDICAL JOURNAL, 2018, 131 (15) : 1781 - U28
  • [2] Pharmacokinetic variability of factor VIII concentrates in Chinese pediatric patients with moderate or severe hemophilia A
    Chen Zhenping
    Huang Kun
    Li Gang
    Zhen Yingzi
    Wu Xinyi
    Ai Di
    Liu Guoqing
    Li Zekun
    Alfonso Iorio
    Wu Runhui
    儿科学研究(英文), 2021, 05 (01) : 38 - 45
  • [3] Pharmacokinetic variability of factor VIII concentrates in Chinese pediatric patients with moderate or severe hemophilia A
    Chen, Zhenping
    Huang, Kun
    Li, Gang
    Zhen, Yingzi
    Wu, Xinyi
    Ai, Di
    Liu, Guoqing
    Li, Zekun
    Alfonso, Iorio
    Wu, Runhui
    PEDIATRIC INVESTIGATION, 2021, 5 (01) : 38 - 45
  • [4] A 5-Year Single-center Experience on the Use of Emicizumab Prophylaxis in Children With Severe Hemophilia A With and Without Factor VIII Inhibitors
    Hasan, Esraa Mohamed Ahmed
    Motwani, Jayashree
    JOURNAL OF PEDIATRIC HEMATOLOGY ONCOLOGY, 2025, 47 (02) : e83 - e89
  • [5] A Real-World Population Pharmacokinetic (PK) Study of Two Recombinant Factor VIII (rFVIII) Concentrates in Boys with Severe Hemophilia a without Inhibitors
    Grassmann, Viviane
    Hajducek, Dagmar M.
    Edginton, Andrea N.
    Bouskill, Vanessa
    Brown, Christine
    Carcao, Manuel
    Lillicrap, David
    O'Rourke, Roxy H.
    Sinha, Roona
    Stoffman, Jayson
    Wakefield, Cindy
    Rand, Margaret L.
    Blanchette, Victor
    BLOOD, 2022, 140 : 8453 - 8455
  • [6] Bayesian pharmacokinetic individualization of prophylaxis with recombinant factor VIII in severe or moderate hemophilia A
    Eduardo Megias-Vericat, Juan
    Marques, Remedios
    Haya, Saturnino
    Rosa Cid, Ana
    Querol, Felipe
    Monte, Emilio
    Bosch, Pau
    Curats, Rafael
    Luis Poveda, Jose
    Bonanad, Santiago
    HAEMOPHILIA, 2018, 24 : 26 - 26
  • [7] The frequency of factor VIII inhibitors in hemophilia A patients in China: a single-center experience over seven years
    Hua, B.
    Yan, Z.
    Zhu, T.
    Wang, S. .
    Fan, L.
    Zhao, Y.
    HAEMOPHILIA, 2008, 14 : 50 - 51
  • [8] Recombinant factor VIII products and inhibitor development in previously untreated boys with severe hemophilia A
    Calvez, Thierry
    Chambost, Herve
    Claeyssens-Donadel, Segolene
    d'Oiron, Roseline
    Goulet, Veronique
    Guillet, Benoit
    Heritier, Virginie
    Milien, Vanessa
    Rothschild, Chantal
    Roussel-Robert, Valerie
    Vinciguerra, Christine
    Goudemand, Jenny
    BLOOD, 2014, 124 (23) : 3398 - 3408
  • [9] BONE MINERAL DENSITY IN YOUNG ADULT PATIENTS WITH SEVERE HEMOPHILIA A -A SINGLE-CENTER STUDY
    Ivanova, H.
    Grudeva-Popova, Z.
    HAEMOPHILIA, 2022, 28 : 42 - 42
  • [10] Factor VIII/factor IX prophylaxis for severe hemophilia
    Carcao, Manuel
    Srivastava, Alok
    SEMINARS IN HEMATOLOGY, 2016, 53 (01) : 3 - 9